drugset / Trial / NCT00320515
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, single arm, open-label Phase 1/2 study of pemetrexed plus cisplatin for patients with unresectable, advanced gastric cancer who had no prior palliative chemotherapy. Phase 1 was designed to determine the optimal dose of pemetrexed for its phase 2, which has been completed and now a total of 60 qualified patients will be enrolled in the phase 2 of this study. The treating physician will determined the maximum number of cycles of pemetrexed plus cisplatin that a patient may receive in this study.
Timeline
- Start
- 2004-03
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 600 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 700 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 800 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 900 mg/m2 | Intravenous |